The International Journal of Clinical Oncology (IJCO) welcomes original and review papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Priority is given to high-quality clinical articles, including prospective randomized studies, rather than retrospective studies. Basic and translational studies will only be accepted if they have obvious clinical significance. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that their content has not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.

Why publish with us

  • We are published in partnership with the Japan Society of Clinical Oncology.
  • Our journal covers all areas of clinical oncology that report the results of novel and timely investigations, and we welcome reports on clinical trials, including prospective randomized studies.
  • We provide a clear and supportive publication process, and ensure high visibility for your publication through marketing, societies, and libraries.

Journal information

Editor-in-Chief
  • Yasumasa Nishimura
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

3.402 (2020)
Impact factor
3.238 (2020)
Five year impact factor
32 days
Submission to first decision
112 days
Submission to acceptance
258,229 (2020)
Downloads

Latest articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Societies, partners and affiliations

About this journal

Electronic ISSN
1437-7772
Print ISSN
1341-9625
Abstracted and indexed in
  1. BFI List
  2. CLOCKSS
  3. CNKI
  4. CNPIEC
  5. Chemical Abstracts Service (CAS)
  6. Dimensions
  7. EBSCO Academic Search
  8. EBSCO Biomedical Reference Collection
  9. EBSCO Discovery Service
  10. EBSCO STM Source
  11. EMBASE
  12. Google Scholar
  13. INIS Atomindex
  14. Japanese Science and Technology Agency (JST)
  15. Journal Citation Reports/Science Edition
  16. Medline
  17. Naver
  18. Norwegian Register for Scientific Journals and Series
  19. OCLC WorldCat Discovery Service
  20. Portico
  21. ProQuest Health & Medical Collection
  22. ProQuest Health Research Premium Collection
  23. ProQuest Medical Database
  24. ProQuest Natural Science Collection
  25. ProQuest Oncogenes and Growth Factors Abstracts
  26. ProQuest Pharma Collection
  27. ProQuest Public Health Database
  28. ProQuest Research Library
  29. ProQuest SciTech Premium Collection
  30. ProQuest-ExLibris Primo
  31. ProQuest-ExLibris Summon
  32. Reaxys
  33. SCImago
  34. SCOPUS
  35. Science Citation Index Expanded (SciSearch)
  36. Semantic Scholar
  37. TD Net Discovery Service
  38. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Japan Society of Clinical Oncology